

ABSTRACT OF THE DISCLOSURE

5 The present invention is directed in part towards  
methods of modulating the function of serine/threonine  
protein kinases with quinazoline-based compounds. The  
methods incorporate cells that express a serine/threonine  
protein kinase, such as RAF. In addition, the invention  
describes methods of preventing and treating  
serine/threonine protein kinase-related abnormal conditions  
in organisms with a compound identified by the invention.  
10 Furthermore, the invention pertains to quinazoline  
compounds and pharmaceutical compositions comprising these  
compounds..